Authors

Discussion

Laser microirradiation assay (LMA) is the gold standard for the study of kinetics of proteins involved in DNA damage response (DDR). The technique has been widely applied to better understand DNA repair inhibitors mode of action. Currently, olaparib, an inhibitor of the PARP enzymes, has been successful in delivering targeted therapy in homologous recombination deficient tumours. Nonetheless the generation of better or alternative targets are still needed and are widely investigated. Here, we use olaparib to show that we can use a modified protocol of the LMA to assess inhibition of DNA repair in live cells. We believe that this modified workflow will allow for the better characterisation of upcoming inhibitors.